Elias Sayias, BSc. CCRA, started his career in the pharmaceutical industry in 2009. He is of Cypriot and Lebanese descent and founded ILIKOS Drug Development Solutions (ILIKOS DDS) in 2019 with the purpose of combining made-to-measure drug development solutions with the highest levels of quality and compliance at the most competitive price point. Throughout his career, Elias held positions of increasing responsibility at renowned Pharmaceutical and Clinical Research Organizations. His focus lies in early stage development through Proof of Concept research and he has experience across a wide range of therapeutic areas as well as studies involving small or large molecules. He has developed skills across several disciplines of clinical research and has partnered with start-up biotechnology and top 10 pharmaceutical companies in North America, Europe and Asia while developing a strong network of collaborators.Linkedin Profile and Industry Recommendations
Able to communicate in 4 languages (English, Greek, French and Arabic) with a multicultural background
First-In-Human to Proof of Concept
Experienced in the transition from pre-clinical to FIH studies and POC programs targeting Patient profiles.
Skilled in several disciplines
Site evaluation/monitoring, contracting, account/project management, corporate/business development.
Excellent track record
Relationships with companies in North America, Europe and Asia with multiple recommendations.
Prowess in study preparation logistics
Study design, protocol/medical writing, regulatory process and support services planning.
ILIKOS is the result of a vision on how drug development solutions should be offered: extremely tailored, adaptive and at a viable cost. Our purpose is to promote positive drug development outcomes by connecting life science companies to the solutions that best fit their needs.
Our focus is to:
1) Offer viable and highly tailored drug development solutions to academic spin-offs, startups, emerging biotechnology and pharmaceutical companies
2) Leverage our geographical location to cover and cultivate relationships across the EU, Africa and Middle East regions.
3) Capitalize on Cyprus’ status as a renowned business hub with a reliable public and private health care system to progress research and present viable clinical trial opportunities to Patients on the island.
There is no straight line in drug development and often the biggest challenge for established or emerging companies is not finding a provider, it’s finding the provider that is best suited to their particular needs. Each company, be it a small start-up or a globally renowned entity, is on its own path and should therefore seek solutions based on its specific objectives. With that in mind, flexibility, responsiveness and quality work define what we offer day in and day out!
Drug development is a team sport but your drug candidate is unique. The solutions we offer are closely aligned to your resources and objectives.
Site Evaluation and Monitoring
Our Team & PartnersAE Corporate Services
AE Corporate Services is a renowned certified chartered accountant firm based in Nicosia that provides accounting, international taxation, business advisory, audit and corporate services. We are working closely with AE Corporate Services founder, Mr. Andreas Charalambous and his team to ensure complete compliance with Cypriot taxation law while strengthening Ilikos’ financial position
Maria Sayia - Corporate Administrator
Maria fulfils the critical role of Corporate Administrator. She holds diplomas from institutions in the UK and Greece in addition to a business administration degree from Cyprus College. As Corporate Administrator, Maria is closely involved in the administration of the company ensuring statutory and regulatory requirements are met and that decisions of the board of directors are implemented.